Sponsor Overview
Explore verified public information about Icahn School of Medicine at Mount Sinai's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 2 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 3 supporting sources.
“# GUIDANCE: Emergency Use, Single Patient/Compassionate Use, Expanded Access for Drugs/Devices”
“Enclosed is an IND application for the compassionate use of DRUG in patient initials, a XX year old man/woman with a preceding history of XXXXX.”
“The Investigational Drug Service (IDS) at Mount Sinai supports all Mount Sinai Health System investigators in the conduct of human clinical trials utilizing medications. These clinical trials may be industry or federally sponsored, investigator initiated trials (IIT), and compassionate use/expanded access drugs.”
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.